MA40136A1 - Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers - Google Patents

Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers

Info

Publication number
MA40136A1
MA40136A1 MA40136A MA40136A MA40136A1 MA 40136 A1 MA40136 A1 MA 40136A1 MA 40136 A MA40136 A MA 40136A MA 40136 A MA40136 A MA 40136A MA 40136 A1 MA40136 A1 MA 40136A1
Authority
MA
Morocco
Prior art keywords
cells
peptides
present
relates
tumor
Prior art date
Application number
MA40136A
Other languages
English (en)
Inventor
Toni Weinschenk
Jens Fritsche
Andrea Mahr
Phillip Müller
Anita Wiebe
Sarah Kutscher
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52630910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40136(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MA40136A1 publication Critical patent/MA40136A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)

Abstract

La présente invention concerne des peptides, des protéines, des acides nucléiques et des cellules pour une utilisation dans des méthodes immunothérapeutiques. La présente invention concerne en particulier l'immunothérapie anticancéreuse. La présente invention concerne en outre des épitopes peptidiques tumoraux de cellules t, seuls ou combinés à d'autres peptides tumoraux, qui peuvent par exemple servir en tant que principes actifs pharmaceutiques au sein de compositions vaccinales destinées à stimuler une réponse immunitaire antitumorale ou destinées à stimuler ex vivo des cellules t ensuite transférées au patient. Des peptides liés aux molécules du complexe majeur d'histocompatibilité (cmh), ou les peptides en tant que tels, peuvent également être les cibles d'anticorps, de récepteurs solubles des cellules t, et d'autres molécules de liaison. La présente invention concerne en particulier plusieurs nouvelles séquences peptidiques et leurs variants dérivés de molécules du hla de classe i et de classe ii de cellules tumorales humaines, lesquels peuvent être utilisés dans des compositions vaccinales pour induire une réponse immunitaire antitumorale, ou comme cibles pour le développement de composés et de cellules pharmaceutiquement/immunologiquement actifs.
MA40136A 2014-12-23 2015-12-16 Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers MA40136A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201423016 2014-12-23
PCT/EP2015/080018 WO2016102272A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers

Publications (1)

Publication Number Publication Date
MA40136A1 true MA40136A1 (fr) 2018-05-31

Family

ID=52630910

Family Applications (3)

Application Number Title Priority Date Filing Date
MA49158A MA49158B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MA41237A MA41237B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers
MA40136A MA40136A1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA49158A MA49158B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MA41237A MA41237B1 (fr) 2014-12-23 2015-12-16 Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers

Country Status (25)

Country Link
US (8) US10064926B2 (fr)
EP (8) EP3236985B2 (fr)
JP (2) JP6906156B2 (fr)
KR (1) KR102284493B1 (fr)
CN (4) CN112646021A (fr)
AR (2) AR103220A1 (fr)
AU (3) AU2015371490B2 (fr)
BR (1) BR112017008972A2 (fr)
CA (1) CA2972126A1 (fr)
CL (1) CL2017001391A1 (fr)
CR (1) CR20170282A (fr)
DK (4) DK3616706T3 (fr)
EA (2) EA202190587A3 (fr)
GB (1) GB201501017D0 (fr)
IL (1) IL250989B (fr)
MA (3) MA49158B1 (fr)
MX (1) MX2017008329A (fr)
PE (1) PE20170940A1 (fr)
PH (1) PH12017500484A1 (fr)
PL (1) PL3236985T5 (fr)
RS (4) RS62448B1 (fr)
SG (1) SG11201703322UA (fr)
SI (3) SI3626729T1 (fr)
TW (1) TWI687436B (fr)
WO (1) WO2016102272A1 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US10813984B2 (en) * 2014-04-24 2020-10-27 Rhode Island Hospital Aspartate-β-hydroxylase induces epitope-specific T cell responses in tumors
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
LT3626729T (lt) 2014-12-23 2021-10-25 Immatics Biotechnologies Gmbh Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
ES2722048T3 (es) 2014-12-23 2019-08-07 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
WO2017079703A1 (fr) 2015-11-05 2017-05-11 Juno Therapeutics, Inc. Vecteurs et cellules immunitaires génétiquement modifiées exprimant des modulateurs de voie métabolique et utilisations en thérapie cellulaire adoptive
PE20181535A1 (es) 2015-12-16 2018-09-26 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
US10676479B2 (en) 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
US11091489B2 (en) 2016-06-20 2021-08-17 Novartis Ag Crystalline forms of a triazolopyrimidine compound
ES2798424T3 (es) 2016-06-20 2020-12-11 Novartis Ag Compuestos de triazolopiridina y usos de estos
KR102674521B1 (ko) * 2016-10-07 2024-06-11 아이오 바이오테크 에이피에스 면역원성 아르기나제 펩타이드
EP3529347A1 (fr) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Extraction par affinité de cellules par un procédé acoustique
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
HRP20230512T8 (hr) * 2017-01-27 2023-09-15 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma
JP2020523022A (ja) * 2017-06-14 2020-08-06 アイカーン スクール オブ メディシン アット マウント サイナイ 免疫療法に反応する肝細胞癌のクラスの検出および治療方法
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
WO2019012141A1 (fr) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Molécule polypeptidique améliorée à double spécificité
WO2019030311A1 (fr) * 2017-08-09 2019-02-14 Pamgene Bv Méthode de prédiction de la réponse de patients atteints d'un carcinome du poumon non à petites cellules à un médicament
GB201713700D0 (en) * 2017-08-25 2017-10-11 Anastasis Biotec Ltd Peptide conjugates
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
AU2018373154A1 (en) 2017-11-22 2020-07-02 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
CA3085784A1 (fr) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Circuit d'attaque et regulateur de transducteur acoustique
WO2019178081A1 (fr) * 2018-03-12 2019-09-19 The Children's Hospital Of Philadelphia Procédés et compositions pour l'utilisation d'auto-antigènes tumoraux en immunothérapie adoptive
DE102018122546B3 (de) * 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
CN113286876A (zh) * 2018-10-26 2021-08-20 T·巴尔 用于生物降解酒精的组合物和方法
CN109663128A (zh) * 2018-11-21 2019-04-23 中国农业大学 一种肺动脉高压标志物及其作为治疗靶点的应用
EP3893925A4 (fr) * 2018-12-13 2023-01-18 Rhode Island Hospital Inhibition de l'asph exprimant la croissance et la progression d'une tumeur
EP3721899A1 (fr) 2019-04-08 2020-10-14 China Medical University Polythérapies comprenant un vaccin basé sur des cellules dendritiques et inhibiteur de point de contrôle immunitaire
CN110850086B (zh) * 2019-11-18 2023-05-02 西安交通大学 一种肝移植术后缺血性胆道病变血清诊断标志物acly的应用
CN114315964B (zh) * 2020-03-18 2023-06-13 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原组合、输卵管癌靶标抗原刺激培养的ctl细胞及其应用
US20230287505A1 (en) 2020-03-30 2023-09-14 Rophelbio Co., Ltd. Biomarker for cancer immunotherapy and use thereof
CA3183756A1 (fr) 2020-05-19 2021-11-25 Amgen Inc. Constructions de liaison a mageb2
CN112063718A (zh) * 2020-09-18 2020-12-11 中国医科大学 Usp14在肝细胞肝癌诊断、预后判断以及治疗中的应用
CN112043722B (zh) * 2020-09-25 2022-02-15 中国医科大学 Prpf6在前列腺癌及去势抵抗前列腺癌治疗中的应用
CN114574486B (zh) * 2020-12-01 2024-04-16 中国科学院大连化学物理研究所 作用于OPLAH的siRNA、DNA及构建物和应用
WO2022212831A1 (fr) 2021-04-02 2022-10-06 Amgen Inc. Constructions de liaison à mageb2
WO2023004326A1 (fr) * 2021-07-19 2023-01-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anticorps mct11 pour traiter l'épuisement fonctionnel de lymphocytes t et améliorer l'immunothérapie anticancéreuse
CN113502300B (zh) * 2021-07-21 2024-02-06 徐州医科大学 一种含有hdac10基因启动子序列和报告基因的重组质粒、制备方法及应用
CN115572764B (zh) * 2022-03-30 2024-06-21 江苏鹍远生物技术有限公司 一组肿瘤检测标志物及其用途

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (da) 1978-12-22 1997-04-14 Biogen Inc Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
CA2163032C (fr) 1993-06-03 2001-02-06 John Landon Fragments d'anticorps a des fins therapeutiques
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ATE244300T1 (de) 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU2061201A (en) * 1999-12-17 2001-06-25 Chiron Corporation Mammalian dishevelled-associated proteins
WO2001062908A2 (fr) 2000-02-22 2001-08-30 Ahuva Nissim Banques d'affichage de phages chimeriques et tcr, reactifs chimeriques et tcr et methodes d'utilisation correspondantes
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2001072768A2 (fr) 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Complexes majeurs d'histocompatibilite monocatenaires de classe 1, constructions les codant et leurs methodes de production
EP1289564B1 (fr) 2000-06-05 2018-07-18 Altor BioScience Corporation Fusions et conjugues de recepteurs de lymphocytes t et procedes d'utilisation correspondants
AU2001276018A1 (en) 2000-07-20 2002-02-05 Regents Of The University Of Minnesota Radiolabeled immunotoxins
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (fr) 2002-02-20 2006-04-26 Dyax Corp Ligands de liaison au complexe mhc-peptide
US7311914B2 (en) 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
AU2003254950A1 (en) * 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
CA2505558C (fr) 2002-11-09 2013-07-02 Avidex Limited Presentation de recepteurs pour l'antigene des lymphocytes t
US20040096982A1 (en) 2002-11-19 2004-05-20 International Business Machines Corporation Methods and apparatus for analysis of mass spectra
PT1581812E (pt) * 2003-01-06 2008-09-22 Wyeth Corp Composições e métodos para diagnóstico e tratamento de cancros do cólon
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090075304A1 (en) 2004-05-27 2009-03-19 Weidanz Jon A Methods of assaying vaccine potency
US20090233318A1 (en) 2004-12-28 2009-09-17 Weidanz Jon A Methods of assaying vaccine potency
ATE461214T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
DE602005016112D1 (de) * 2005-09-05 2009-10-01 Immatics Biotechnologies Gmbh Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
EP2520935A3 (fr) 2006-08-09 2013-02-13 Homestead Clinical Corporation Protéines spécifiques d'organes et leurs procédés d'utilisation
CN101765434B (zh) * 2007-07-27 2014-12-17 伊玛提克斯生物技术有限公司 抗肿瘤相关肽及相关抗癌疫苗组合物
MX2010001086A (es) * 2007-07-27 2010-04-09 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra tumores neuronales y cerebrales.
WO2009026547A1 (fr) 2007-08-22 2009-02-26 Receptor Logi, Ltd. Procédés d'analyse de l'activité de vaccin
PL2201100T3 (pl) * 2007-09-14 2016-10-31 Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu
WO2009108372A2 (fr) * 2008-02-27 2009-09-03 Receptor Logic, Inc. Anticorps imitant les récepteurs des lymphocytes t, leurs procédés de production et d’utilisation
ES2554981T3 (es) * 2008-03-27 2015-12-28 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra tumores neuronales y cerebrales
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
WO2009151487A1 (fr) * 2008-06-13 2009-12-17 Receptor Logic, Inc. Procédés de dosage de la puissance d’un vaccin
DE102008049136B4 (de) 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
WO2011060329A1 (fr) 2009-11-14 2011-05-19 Kuang-Yuh Chyu Procédés et systèmes d'immunomodulation pour le traitement et/ou la prévention de l'athérosclérose
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
BR112013010213A2 (pt) 2010-10-26 2019-09-24 Technion Research & Development Foundation Ltd anticorpos que unem ligantes solúveis de receptores de célula t
EP2637689A2 (fr) 2010-11-12 2013-09-18 Cedars-Sinai Medical Center Procédés et systèmes immunomodulateurs pour le traitement et/ou la prévention de l'hypertension
AU2011325948A1 (en) 2010-11-12 2013-05-30 Cedars-Sinai Medical Center Immunomodulatory compositions, methods and systems comprising immunogenic fragments of Apob100
JP2013544243A (ja) 2010-11-12 2013-12-12 シーダース シナイ メディカル センター 動脈瘤の治療及び／又は予防のための免疫調節方法及びシステム
WO2013057586A1 (fr) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions et procédés de production de récepteurs solubles des lymphocytes t
EP2788012A4 (fr) * 2011-11-11 2015-08-05 Cedars Sinai Medical Center Compositions et méthodes de traitement de maladies rénales
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
AU2013312529A1 (en) * 2012-09-05 2015-04-16 The University Of Birmingham Target peptides for colorectal cancer therapy and diagnostics
US20190292535A1 (en) 2012-11-08 2019-09-26 Roche Diagnostics Operations, Inc. Nucleic acids encoding chimeric polypeptides for library screening
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
US9134326B2 (en) * 2013-03-14 2015-09-15 Battelle Memorial Institute Biomarkers for liver fibrosis
EP2808392A1 (fr) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamères et utilisation de ces aptamères dans le diagnostic et le traitement du cancer
CN103739667B (zh) * 2013-09-24 2017-08-25 上海宇研生物技术有限公司 卵巢癌特异的肿瘤抗原肽及其制备方法
ES2740930T3 (es) 2014-03-14 2020-02-07 Immunocore Ltd Bibliotecas de TCR
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
US20180179283A1 (en) 2015-06-08 2018-06-28 Adicet Bio Inc. T cell receptor like antibodies having fine specificity
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
ES2891321T3 (es) 2016-04-08 2022-01-27 Adaptimmune Ltd Receptores de células T
CN117603339A (zh) 2016-04-08 2024-02-27 艾达普特免疫有限公司 T细胞受体
EP3440104B2 (fr) 2016-04-08 2023-06-14 Adaptimmune Limited Récepteurs des lymphocytes t
EP3491856A4 (fr) 2016-07-27 2020-01-22 Sharp Kabushiki Kaisha Procédés et appareil de télécommunication sans fil utilisant une étiquette de valeur d'information système
US20200325244A1 (en) 2020-05-18 2020-10-15 Abexxa Biologics, Inc. Antibodies and methods of use thereof
EP3573997A4 (fr) 2017-01-24 2020-12-09 Abexxa Biologics, Inc. Méthodes et compositions destinées à cibler un complexe comprenant un hla-i non classique et un néo-antigène dans le traitement du cancer
WO2018225732A1 (fr) 2017-06-05 2018-12-13 国立大学法人三重大学 Protéine de liaison à l'antigène reconnaissant un peptide dérivé d'un mage-a4
KR20200024905A (ko) 2017-07-04 2020-03-09 큐어백 아게 신규 핵산 분자
CA3072816A1 (fr) 2017-08-18 2019-02-21 Gritstone Oncology, Inc. Proteines de liaison d'antigene ciblant des antigenes partages
US20190201443A1 (en) 2017-09-06 2019-07-04 California Institute Of Technology Signaling and antigen-presenting bifunctional receptors (sabr)
WO2019133853A1 (fr) 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Protéines se liant à l'antigène ciblant des antigènes partagés
EP3784255A4 (fr) 2018-04-19 2022-06-22 Board of Regents, The University of Texas System Récepteurs de lymphocytes t spécifiques de mage-b2 et leurs utilisations
EP3796927A4 (fr) 2018-05-23 2022-04-20 Gritstone bio, Inc. Antigènes partagés
US20200291116A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US20200291127A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US20200291128A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof

Also Published As

Publication number Publication date
MA49158A (fr) 2020-03-25
EA201791150A1 (ru) 2018-03-30
MA41237A (fr) 2017-11-01
SI3236985T2 (sl) 2023-01-31
SI3626729T1 (sl) 2021-11-30
PH12017500484A1 (en) 2017-08-07
AR122964A2 (es) 2022-10-19
EP3236985B2 (fr) 2022-09-07
MA49158B1 (fr) 2021-12-31
US20190000947A1 (en) 2019-01-03
KR102284493B1 (ko) 2021-08-02
EP3626731A1 (fr) 2020-03-25
PL3236985T4 (pl) 2020-12-14
CN112538109A (zh) 2021-03-23
DK3545965T3 (da) 2021-09-13
EP3236985B1 (fr) 2019-09-25
AR103220A1 (es) 2017-04-26
EP3545965A3 (fr) 2019-12-25
EP3626729B1 (fr) 2021-09-08
BR112017008972A2 (pt) 2018-01-16
CN107001414A (zh) 2017-08-01
EA202190587A2 (ru) 2021-06-30
EP3236985A1 (fr) 2017-11-01
IL250989B (en) 2021-04-29
RS59836B2 (sr) 2023-01-31
MA41237B1 (fr) 2019-12-31
DK3616706T3 (da) 2021-11-15
EP3616706A1 (fr) 2020-03-04
EP3616706B1 (fr) 2021-10-13
US20200376103A1 (en) 2020-12-03
WO2016102272A1 (fr) 2016-06-30
EP3545965B1 (fr) 2021-07-21
IL250989A0 (en) 2017-04-30
US11406693B2 (en) 2022-08-09
PL3236985T5 (pl) 2023-03-06
US20160250307A1 (en) 2016-09-01
US10064926B2 (en) 2018-09-04
AU2020213295B2 (en) 2022-09-01
SI3236985T1 (sl) 2020-01-31
DK3626731T3 (da) 2021-11-22
EP3715357A1 (fr) 2020-09-30
EA202190587A3 (ru) 2021-09-30
CN112646021A (zh) 2021-04-13
MX2017008329A (es) 2017-10-26
AU2015371490B2 (en) 2020-08-13
CL2017001391A1 (es) 2017-12-29
AU2015371490A1 (en) 2017-03-23
US11786583B2 (en) 2023-10-17
US20180207253A1 (en) 2018-07-26
US20200405831A1 (en) 2020-12-31
DK3626729T3 (da) 2021-11-01
CN112646025A (zh) 2021-04-13
RS59836B1 (sr) 2020-02-28
CA2972126A1 (fr) 2016-06-30
US20180207252A1 (en) 2018-07-26
EP3626730A1 (fr) 2020-03-25
EP3626729A1 (fr) 2020-03-25
RS62508B1 (sr) 2021-11-30
US20210268089A1 (en) 2021-09-02
PE20170940A1 (es) 2017-07-13
SG11201703322UA (en) 2017-07-28
JP2021104033A (ja) 2021-07-26
EP3620168A1 (fr) 2020-03-11
SI3545965T1 (sl) 2021-11-30
PL3236985T3 (pl) 2020-04-30
RS62448B1 (sr) 2021-11-30
RS62237B1 (sr) 2021-09-30
AU2020213294A1 (en) 2020-09-03
JP2018509135A (ja) 2018-04-05
EP3626731B1 (fr) 2021-09-08
AU2020213294B2 (en) 2022-10-06
TW201629096A (zh) 2016-08-16
US20170080070A1 (en) 2017-03-23
KR20170090447A (ko) 2017-08-07
JP6906156B2 (ja) 2021-07-21
AU2020213295A1 (en) 2020-09-03
CR20170282A (es) 2018-01-29
TWI687436B (zh) 2020-03-11
GB201501017D0 (en) 2015-03-04
EP3545965A2 (fr) 2019-10-02

Similar Documents

Publication Publication Date Title
MA40136A1 (fr) Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers
MA43490A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA46648A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
MA44551A1 (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers
MA41521A1 (fr) Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers
MA43457A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA44693A1 (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers
MA41522A1 (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l'œsophage et d'autres cancers
MA46022B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MA41520B2 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA41393A1 (fr) Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers
MA43330A1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA43435B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003)
MA43719B1 (fr) Peptide à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et le cancer du poumon à petites cellules
MA42294B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA43090A1 (fr) Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers
MA43328A1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA47367B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA49155B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MA41664A1 (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers
MA46503A1 (fr) Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers
MA43596A1 (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l'œsophage et d'autres cancers